Alnylam Pharmaceuticals (ALNY)
Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.
$247.61
vs last close−4.04 (−1.61%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 100.14% | 134.00M shares | |
|---|---|---|---|
| 828 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.24% | 316.0K shares | |
| 19 holders · as of Sep 22, 2026 | |||
| Adds to | 100.38% | ||
133.81M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 100.38%; nothing is left for Other.
13F, as of Jun 30, 2026
828 holders · 134.00M shares · 89 new positions · 411 increased · 287 reduced · 90 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 15.02M | 11.23% | +444.8K | Aug 13, 2026 |
| Capital World Investors | 11.14M | 8.33% | +342.5K | Aug 12, 2026 |
| BlackRock, Inc. | 10.91M | 8.15% | +462.8K | Aug 7, 2026 |
| Capital Research Global Investors | 9.75M | 7.29% | +279.5K | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 6.54M | 4.89% | +47.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.03M | 4.51% | +82.8K | Aug 13, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.64M | 4.22% | +448.8K | Aug 14, 2026 |
| Invesco Ltd. | 3.75M | 2.81% | +970.9K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 11.00% | 14.64M | 13G | May 6, 2026 |
| Capital World Investors | 8.20% | 10.92M | 13G | May 14, 2026 |
| Capital Research Global Investors | 7.10% | 9.47M | 13G | May 14, 2026 |
| Vanguard Capital Management | 5.35% | 7.10M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 1, 2026 | David E. I. Pyottdirector | Sale · 5 lots | 3,830 | $299.18 | 1,582 |
| Apr 6, 2026 | Melissa McLaughlinofficer: Chief Human Resources Officer | Sale · 5 lots | 2,286 | $330.42 | 9,443 |
| Apr 2, 2026 | Melissa McLaughlinofficer: Chief Human Resources Officer | Sale · 9 lots | 1,624 | $319.59 | 11,729 |
| Mar 5, 2026 | Kevin Joseph Fitzgeraldofficer: CSO & EVP, Head of Research | Sale · 4 lots | 658 | $323.98 | 20,569 |
| Mar 4, 2026 | Kevin Joseph Fitzgeraldofficer: CSO & EVP, Head of Research | Sale · 8 lots | 633 | $323.08 | 21,227 |
| Mar 4, 2026 | Tolga Tangulerofficer: EVP, Chief Commercial Officer | Sale · 8 lots | 2,309 | $323.08 | 34,297 |
| Mar 4, 2026 | Jeffrey V. Poultonofficer: EVP, Chief Financial Officer | Sale · 8 lots | 2,468 | $323.08 | 61,805 |
| Mar 4, 2026 | Yvonne Greenstreetdirector, officer: Chief Executive Officer | Sale · 8 lots | 2,933 | $323.08 | 95,695 |
| Mar 5, 2026 | Pushkal Gargofficer: EVP Chief R&D | Sale · 4 lots | 2,404 | $323.96 | 18,693 |
| Mar 4, 2026 | Pushkal Gargofficer: EVP Chief R&D | Sale · 8 lots | 2,309 | $323.08 | 21,097 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Sen. Cory Booker · NJ | Sale | $1,001 – $15,000 | Spouse | Aug 11, 2026 | Sep 9, 2026 |